EGFR and breast adenocarcinoma: Vitality/viability profiles for chemotherapeutic-resistant mammary adenocarcinoma were compatible with the concept that gemcitabine was internalized independently but simultaneously at two separate endogenous trophic membrane receptor sites (e.g. EGFR, HER2/neu) by mechanisms of receptor-mediated endocytosis.